DOCSLIB.ORG

Induction Or Aggravation of Other Immune-Mediated Disorders by Disease-Modifying Therapy in Treatment of Multiple Sclerosis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Induction Or Aggravation of Other Immune-Mediated Disorders by Disease-Modifying Therapy in Treatment of Multiple Sclerosis Iranian Journal Review Article of Neurology Iran J Neurol 2018; 17(3): 129-36 Induction or aggravation of other Received: 25 Feb. 2018 immune-mediated disorders by Accepted: 07 May 2018 disease-modifying therapy in treatment of multiple sclerosis Seyed Mohammad Baghbanian1, Mohammad Ali Sahraian2 1 Bualicina Hospital, Mazandaran University of Medical sciences, Sari, Iran 2 Multiple Sclerosis Research Centre, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran Keywords system which, in over 85% of circumstances, Interferon-Beta; Glatiramer Acetate; Autoimmune initially presents as relapsing neurological Disease; Multiple Sclerosis disability followed by remission phases.1-3 The disease affects young adults and is more common among women.4 There is no cure for MS, and treatment concentrates on treating relapses, Abstract diminishing the progression of disability and Interferon beta (IFN-β) and glatiramer acetate (GA) secondary symptom management. Interferon beta are the primary therapeutic immunomodulatory (IFN-β) and glatiramer acetate (GA) are the agents that interfere with relapsing-remitting primary therapeutic immunomodulatory agents multiple sclerosis (RRMS), and the most commonly- used drugs as well. Induction or aggravation of other that interfere with relapsing-remitting multiple immune-mediated diseases has been reported sclerosis (RRMS), and the most commonly-used 5 following INF-β administration. We have reviewed drugs as well. the reported cases to notify the treating physicians Isaacs and Lindenmann,6 the discovers of INF, about these rare adverse events. Although co-morbid use this term to explain the antiviral replication autoimmune disorders have been reported in properties of these biologically-active substances. patients with MS, the pro-inflammatory role of It features an acceptable risk profile, is well disease-modifying drugs, especially INF-β, could tolerated, and is effective in decreasing the affect and enhance this co-occurrence. Clinical or activity of RRMS. This makes INF the first choice laboratory autoimmunity histories suggest the use of for disease-modifying therapy in MS. GA over INF-β as the treatment of choice. GA is a synthetic polypeptide composed of four amino acids in a mixture resembling myelin basic Introduction protein.7 Many trials have shown that GA can Multiple sclerosis is an inflammatory reduce the relapse rate, disability progression and demyelinating disease of the central nervous ameliorate the course of the disease as indicated by Iranian Journal of Neurology © 2018 Corresponding Author: Seyed Mohammad Baghbanian Email: [email protected] Email: [email protected] http://ijnl.tums.ac.ir 06 July Autoimmune disorders aggravation by disease-modifying treatment of MS MRI findings.8 GA is one of the most prescribed histopathology from arcuate and polycyclic disease-modifying-therapies for multiple sclerosis.9 erythematous scaly plaque on the face, trunk, and Injection site reaction is the most frequent side upper extremities of a 43-year-old woman with effect of IFN and GA. Other side effects include a RRMS under treatment with intramuscular (IM) flu-like syndrome, lymphopenia caused by IFN as INF-b1a who presented with interface well as hepatic failure, hepatitis and elevated liver dermatitis.15 Lupus erythematosus profundus enzymes. These have been reported for both (lupus panniculitis) was diagnosed when a treatments, although they are more common for 19-year-old woman with RRMS under treatment IFN.10 Induction or aggravation of other immune with INF-β1b presented with painful nodules on mediated diseases have been reported following the face, both shoulders, and upper limbs; a skin INF beta administration. Here we have reviewed biopsy suggested lobular panniculitis.16 Two cases the reported cases to notify the treating physicians of lupus-like reaction to INF at the injection site about these rare adverse events. In many were reported in patients with MS being treated instances continuation of INF following with INF-β1b.17 SLE induced by INF-b1 therapy appearance of a new autoimmune disease may was reported in a 34-year-old patient with RRMS aggravate the condition and INF therapy should who developed myalgia associated with wrist be promptly stopped to prevent further damage. synovitis with no skin involvement.18 Psoriasis: Case reports have shown an Review of case reports association between psoriasis and MS. In most Arthritis: A 37-year-old woman with MS cases, the psoriasis presented before MS, and it presented with isolated temporomandibular joint appeared possible to define co-morbidity, but INF- arthritis two weeks after starting IFN-β1a therapy. induced psoriasis was not excluded.19 Exacerbation It resolved completely shortly after IFN of cutaneous psoriasis and psoriatic arthritis has discontinuation, and did not recur after switching been reported in patients with MS.20-22 treatment to GA.11 A 38-year-old woman with Inflammatory bowel disease (IBD): Severe RRMS presented with left pre-patellar bursitis colitis caused by Crohn’s disease was reported in with no particular involvement three months after a patient with MS treated with IFN-β.23 initiation of IFN-β1a.11 A 29-year-old woman with Aggravation and development of ulcerations was RRMS presented with severe acute-onset reported after treatment with IFN-β1a.24,25 A case arthralgia, swelling of both knees, and of rapid-onset ulcerative colitis was reported one inflammatory synovial fluid reaction three weeks week after INF-β1a therapy. The time of onset of after beginning treatment with IFN-β1b. The ulcerative colitis was from one day after IFN condition disappeared a few days after initiation to one week after discontinuation of the discontinuation of IFN.12 Seropositive therapy.26 Celiac disease was reported in a 36-year polyarthritis with high erythrocyte sedimentation old woman with RRMS after one month of rate (ESR), elevated C-reactive protein (CRP), and treatment with IFN-β1b.27 MS concomitant with high rheumatic factor (RF) titer was reported in a celiac disease has been recently diagnosed more 42-year-old woman with RRMS after 30 months of often than expected.27 A 27-year-old woman with treatment with INF-β1b.12 Animal experiments RRMS treated with GA for 2 years presented with have shown that GA could exacerbate abdominal pain, diarrhea, fever, and weight loss. autoimmune arthritis. These findings suggest that A colonoscopy showed diffuse right-sided colitis GA should be used with great caution in patients and ileitis, and the biopsy was compatible with with MS and other autoimmune complications.13 Crohn’s disease. This report emphasized that Systemic lupus erythematosus (SLE): A Crohn’s disease might be an adverse event related 43-year-old woman with RRMS under treatment to treatment with GA.28 with INF-β1a was diagnosed with drug-induced Sarcoidosis: IFN-β has been reported to induce SLE (DILE) four weeks after developing synovitis, sarcoidosis. The duration of IFN-β treatment at fever, myalgia, and facial edema. Laboratory test the time of diagnosis varied from results were positive for antinuclear antibodies 8 months to three years. The most common (ANA) and anti-double stranded DNA antibody presentation included pulmonary manifestations, (anti-dsDNA). After discontinuation of INF, the although hepatic, and bone involvement. symptoms resolved completely.14 A diagnosis of Transbronchial, mediastinal, and paratracheal cutaneous SLE was confirmed by lesional skin lymph node and skin biopsies confirmed the 130 Iran J Neurol, Vol. 17, No. 3 (2018) http://ijnl.tums.ac.ir 06 July S.M. Baghbanian and M.A. Sahraian diagnoses.29,30 Cutaneous and pulmonary patients presented with generalized urticaria, sarcoidosis with erythema nodosum in the lower nausea, and hypotension upon the first limbs, breast abscesses, and unilateral pulmonary administration of GA. In a third patient, after six adenopathy were reported in a 33-year-old woman months of GA interruption, an immediate with RRMS treated with INF-β1b for 2.5 years.31 reaction presented with eyelid edema 20 minutes Susac syndrome: Exacerbation of Susac after GA administration.46 syndrome retinopathy has been reported in a Autoimmune hepatitis (AIH): Features of 23-year-old man misdiagnosed with MS who was autoimmune liver disease and primary biliary treated with IFN-β1a for 15 months. Two weeks cirrhosis after 33 months of administration of IFN- after IFN-β discontinuation, the visual field and β was reported in a 42-year-old woman with fluorescein angiography indicated complete RRMS. The strong positivity of antimitochondrial recovery.32 antibodies was consistent with primary biliary Scleromyxedema: Scleromyxedema was reported cirrhosis and positive ANA along with elevated in a 37-year-old woman with RRMS under aspartate aminotransferase (AST) and alanine treatment with IFN-β1a for three years. The patient aminotransferase (ALT) were suggestive of AIH; recovered after discontinuation of IFN-β1a but clinical symptoms of acute liver injury did not treatment.33 present.47 A 20-year-old woman and a 47-year-old Dermatomyositis: A violaceous skin eruption man with RRMS treated with IFN-β1a presented associated with periorbital edema and proximal with elevated liver function tests. The first patient muscle weakness presented in a 57-year-old man presented with asthenia, progressive jaundice, with RRMS under treatment with IFN-β1a. Skin nausea, and abdominal discomfort along with re- biopsy diagnosed it as dermatomyositis. Clinical elevated liver
Load more

Recommended publications
  • Update on Challenging Disorders of Pigmentation in Skin of Color Heather Woolery-Lloyd, M.D
    Update on Challenging Disorders of Pigmentation in Skin of Color Heather Woolery-Lloyd, M.D. Director of Ethnic Skin Care Voluntary Assistant Professor Miller/University of Miami School of Medicine Department of Dermatology and Cutaneous Surgery What Determines Skin Color? What Determines Skin Color? No significant difference in the number of melanocytes between the races 2000 epidermal melanocytes/mm2 on head and forearm 1000 epidermal melanocytes/mm2 on the rest of the body differences present at birth Jimbow K, Quevedo WC, Prota G, Fitzpatrick TB (1999) Biology of melanocytes. In I. M. Freedberg, A.Z. Eisen, K. Wolff,K.F. Austen, L.A. Goldsmith, S. I. Katz, T. B. Fitzpatrick (Eds.), Dermatology in General Medicine 5th ed., pp192-220, New York, NY: McGraw Hill Melanosomes in Black and White Skin Black White Szabo G, Gerald AB, Pathak MA, Fitzpatrick TB. Nature1969;222:1081-1082 Jimbow K, Quevedo WC, Prota G, Fitzpatrick TB (1999) Biology of melanocytes. In I. M. Freedberg, A.Z. Eisen, K. Wolff, K.F. Austen, L.A. Goldsmith, S. I. Katz, T. B. Fitzpatrick (Eds.), Dermatology in General Medicine 5th ed., pp192- 220, New York, NY: McGraw Hill Role of Melanin-Advantages Melanin absorbs and scatters energy from UV and visible light to protect epidermal cells from UV damage Disadvantages Inflammation or injury to the skin is almost immediately accompanied by alteration in pigmentation Hyperpigmentation Hypopigmentation Dyschromias Post-Inflammatory hyperpigmentation Acne Melasma Lichen Planus Pigmentosus Progressive Macular Hypomelanosis
    [Show full text]
  • Frequency of Different Types of Facial Melanoses Referring to the Department of Dermatology and Venereology, Nepal Medical Colle
    Amatya et al. BMC Dermatology (2020) 20:4 https://doi.org/10.1186/s12895-020-00100-3 RESEARCH ARTICLE Open Access Frequency of different types of facial melanoses referring to the Department of Dermatology and Venereology, Nepal Medical College and Teaching Hospital in 2019, and assessment of their effect on health-related quality of life Bibush Amatya* , Anil Kumar Jha and Shristi Shrestha Abstract Background: Abnormalities of facial pigmentation, or facial melanoses, are a common presenting complaint in Nepal and are the result of a diverse range of conditions. Objectives: The objective of this study was to determine the frequency, underlying cause and impact on quality of life of facial pigmentary disorders among patients visiting the Department of Dermatology and Venereology, Nepal Medical College and Teaching Hospital (NMCTH) over the course of one year. Methods: This was a cross-sectional study conducted at the Department of Dermatology and Venereology, NMCT H. We recruited patients with facial melanoses above 16 years of age who presented to the outpatient department. Clinical and demographic data were collected and all the enrolled participants completed the validated Nepali version of the Dermatology Life Quality Index (DLQI). Results: Between January 5, 2019 to January 4, 2020, a total of 485 patients were recruited in the study. The most common diagnoses were melasma (166 patients) and post acne hyperpigmentation (71 patients). Quality of life impairment was highest in patients having melasma with steroid induced rosacea-like dermatitis (DLQI = 13.54 ± 1.30), while it was lowest in participants with ephelides (2.45 ± 1.23). Conclusion: Facial melanoses are a common presenting complaint and lead to substantial impacts on quality of life.
    [Show full text]
  • In Dermatology Visit with Me to Discuss
    From time to time new treatments surface for any medical field, and the last couple of years have seen new treatments emerge, or new applications for familiar treatments. I wanted to summarize some of these New Therapies widely available remedies and encourage you to schedule a in Dermatology visit with me to discuss. Written by Board Certified Dermatologist James W. Young, DO, FAOCD Nicotinamide a significant reduction in melanoma in Antioxidants Nicotinamide (niacinamide) is a form high risk skin cancer patients at doses Green tea, pomegranate, delphinidin of vitamin B3. The deficiency of vitamin more than 600 and less than 4,000 IU and fisetin are all under current study for daily. B3 causes pellagra, a condition marked either oral or topical use in the reduction by 4D’s – (photo) Dermatitis, Dementia, Polypodium Leucotomos of the incidence of skin cancer, psoriasis Diarrhea and (if left untreated) Death. and other inflammatory disorders. I’ll be Polypodium leucotomos is a Central This deficiency is rare in developed sure to keep patients updated. countries, but is occasionally seen America fern that is available in several in alcoholism, dieting restrictions, or forms, most widely as Fernblock What Are My Own Thoughts? malabsorption syndromes. Nicotinamide (Amazon) or Heliocare (Walgreen’s and I take Vitamin D 1,000 IU and Heliocare does not cause the adverse effects of Amazon) and others. It is an antioxidant personally. Based on new research, I Nicotinic acid and is safe at doses up to that reduces free oxygen radicals and have also added Nicotinamide which 3,000mg daily. may reduce inflammation in eczema, dementia, sunburn, psoriasis, and vitiligo.
    [Show full text]
  • Psoriasis and Vitiligo: an Association Or Coincidence?
    igmentar f P y D l o is a o n r r d e u r o s J Solovan C, et al., Pigmentary Disorders 2014, 1:1 Journal of Pigmentary Disorders DOI: 10.4172/jpd.1000106 World Health Academy ISSN: 2376-0427 Letter To Editor Open Access Psoriasis and Vitiligo: An Association or Coincidence? Caius Solovan1, Anca E Chiriac2, Tudor Pinteala2, Liliana Foia2 and Anca Chiriac3* 1University of Medicine and Pharmacy “V Babes” Timisoara, Romania 2University of Medicine and Pharmacy “Gr T Popa” Iasi, Romania 3Apollonia University, Nicolina Medical Center, Iasi, Romania *Corresponding author: Anca Chiriac, Apollonia University, Nicolina Medical Center, Iasi, Romania, Tel: 00-40-721-234-999; E-mail: [email protected] Rec date: April 21, 2014; Acc date: May 23, 2014; Pub date: May 25, 2014 Citation: Solovan C, Chiriac AE, Pinteala T, Foia L, Chiriac A (2014) Psoriasis and Vitiligo: An Association or Coincidence? Pigmentary Disorders 1: 106. doi: 10.4172/ jpd.1000106 Copyright: © 2014 Solovan C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Letter to Editor Dermatitis herpetiformis 1 0.08% Sir, Chronic urticaria 2 0.16% The worldwide occurrence of psoriasis in the general population is Lyell syndrome 1 0.08% about 2–3% and of vitiligo is 0.5-1%. Coexistence of these diseases in the same patient is rarely reported and based on a pathogenesis not Quincke edema 1 0.08% completely understood [1].
    [Show full text]
  • Pityriasis Alba Revisited: Perspectives on an Enigmatic Disorder of Childhood
    Pediatric ddermatologyermatology Series Editor: Camila K. Janniger, MD Pityriasis Alba Revisited: Perspectives on an Enigmatic Disorder of Childhood Yuri T. Jadotte, MD; Camila K. Janniger, MD Pityriasis alba (PA) is a localized hypopigmented 80 years ago.2 Mainly seen in the pediatric popula- disorder of childhood with many existing clinical tion, it primarily affects the head and neck region, variants. It is more often detected in individuals with the face being the most commonly involved with a darker complexion but may occur in indi- site.1-3 Pityriasis alba is present in individuals with viduals of all skin types. Atopy, xerosis, and min- all skin types, though it is more noticeable in those with eral deficiencies are potential risk factors. Sun a darker complexion.1,3 This condition also is known exposure exacerbates the contrast between nor- as furfuraceous impetigo, erythema streptogenes, mal and lesional skin, making lesions more visible and pityriasis streptogenes.1 The term pityriasis alba and patients more likely to seek medical atten- remains accurate and appropriate given the etiologic tion. Poor cutaneous hydration appears to be a elusiveness of the disorder. common theme for most riskCUTIS factors and may help elucidate the pathogenesis of this disorder. The Epidemiology end result of this mechanism is inappropriate mel- Pityriasis alba primarily affects preadolescent children anosis manifesting as hypopigmentation. It must aged 3 to 16 years,4 with onset typically occurring be differentiated from other disorders of hypopig- between 6 and 12 years of age.5 Most patients are mentation, such as pityriasis versicolor alba, vitiligo, younger than 15 years,3 with up to 90% aged 6 to nevus depigmentosus, and nevus anemicus.
    [Show full text]
  • Alopecia Areata, Atopic Dermatitis and Vitiligo (Global) Competitive Grant Program - Internal Pfizer Review Process
    Pfizer Announces a Research Grant RFP Alopecia Areata, Atopic Dermatitis and Vitiligo (Global) Competitive Grant Program - internal Pfizer review process I. Background Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP. For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program. Alopecia3 Areata, Atopic Dermatitis and Vitiligo (Global) II. Eligibility Geographic Scope: Global (including U.S.A.) Applicant Eligibility • Only organizations are eligible to receive grants, not individuals or Criteria medical practice groups. • The applicant (PI) must have a
    [Show full text]
  • Osteoporosis in Skin Diseases
    International Journal of Molecular Sciences Review Osteoporosis in Skin Diseases Maria Maddalena Sirufo 1,2, Francesca De Pietro 1,2, Enrica Maria Bassino 1,2, Lia Ginaldi 1,2 and Massimo De Martinis 1,2,* 1 Department of Life, Health and Environmental Sciences, University of L’Aquila, 67100 L’Aquila, Italy; [email protected] (M.M.S.); [email protected] (F.D.P.); [email protected] (E.M.B.); [email protected] (L.G.) 2 Allergy and Clinical Immunology Unit, Center for the Diagnosis and Treatment of Osteoporosis, AUSL 04 64100 Teramo, Italy * Correspondence: [email protected]; Tel.: +39-0861-429548; Fax: +39-0861-211395 Received: 1 June 2020; Accepted: 1 July 2020; Published: 3 July 2020 Abstract: Osteoporosis (OP) is defined as a generalized skeletal disease characterized by low bone mass and an alteration of the microarchitecture that lead to an increase in bone fragility and, therefore, an increased risk of fractures. It must be considered today as a true public health problem and the most widespread metabolic bone disease that affects more than 200 million people worldwide. Under physiological conditions, there is a balance between bone formation and bone resorption necessary for skeletal homeostasis. In pathological situations, this balance is altered in favor of osteoclast (OC)-mediated bone resorption. During chronic inflammation, the balance between bone formation and bone resorption may be considerably affected, contributing to a net prevalence of osteoclastogenesis. Skin diseases are the fourth cause of human disease in the world, affecting approximately one third of the world’s population with a prevalence in elderly men.
    [Show full text]
  • RIPE for the PICKING Experts Profile the Future of Biologic Treatments
    RIPE FOR THE PICKING Experts profile the future of biologic treatments 22 DERMATOLOGY WORLD // September 2015 www.aad.org/dw BY VICTORIA HOUGHTON, ASSISTANT MANAGING EDITOR John Harris, MD, PhD, assistant professor of medicine at the University of Massachusetts in the division of dermatology — like many dermatologists — has watched the impressive evolution of treatments for psoriasis over the last decade with anticipation. “We initially had very broad immunosuppressants that were somewhat effective in some patients, but they also had significant side effects,” Dr. Harris said. However, “The onset of biologics and other targeted therapies has been incredible. They’ve revolutionized treatment for psoriasis.” However, while physicians are enthusiastic about the progress of these treatments for psoriasis, there is also hope that interest in developing these innovative therapies is increasingly shifting to other skin conditions. “Pharmaceutical companies have to start looking elsewhere, given how good current psoriasis therapies are,” Dr. Harris said. “The real room for growth is in other diseases.” As psoriasis has paved the way for an interest in developing biologic and other targeted treatments in skin conditions, physicians are anticipating a promising future for these treatments in the following conditions: Atopic dermatitis Hidradenitis suppurativa Chronic urticaria Vitiligo Dermatomyositis >> Alopecia areata DERMATOLOGY WORLD // September 2015 23 RIPE FOR THE PICKING Atopic dermatitis 133; 6:1626-34). The study showed that by blocking the According to Lawrence Eichenfield, MD, professor of immune pathways with CsA, the molecular abnormalities dermatology and pediatrics at the University of California, with AD skin barrier genes, such as filaggrin and loricrin, San Diego and chief of pediatric and adolescent dermatology normalized.
    [Show full text]
  • Case Report Vitiligo Appearing After Oral Isotretinoin Therapy for Acne
    Hindawi Case Reports in Dermatological Medicine Volume 2018, Article ID 3697260, 3 pages https://doi.org/10.1155/2018/3697260 Case Report Vitiligo Appearing after Oral Isotretinoin Therapy for Acne Amal A. Kokandi Department of Dermatology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia Correspondence should be addressed to Amal A. Kokandi; [email protected] Received 15 June 2018; Revised 30 June 2018; Accepted 10 July 2018; Published 12 July 2018 Academic Editor: Jacek Cezary Szepietowski Copyright © 2018 Amal A. Kokandi. Tis is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Isotretinoin is an efective treatment for severe and scarring acne. In this report, we describe a case developing vitiligo afer isotretinoin therapy for scarring acne. It is not known whether this was a coincidence or might be precipitated by the treatment. 1. Introduction Afer initial laboratory works (lipid profle and liver enzymes) which were in the normal range, she was started on Isotretinoin is an efective therapy for severe acne. It has the 20 mg isotretinoin. She was maintained on 20 mg (0.5 mg/kg) best infuence on the health-related quality of life in acne for 6 months. She had mild chelitis and skin dryness and patients [1]. Some side efects of isotretinoin are well known complained of mild hair fall. Repeated liver enzymes and lipid and predictable such as chelitis and xerosis. Other side efects profle afer one month and 4 months were within normal are known but less common such as hyperlipidemia.
    [Show full text]
  • Chronic Actinic Damage in Pigmented And
    erimenta xp l D E e r & m l a a t c o i l n o i Journal of Clinical & Experimental Garcia-Romero et al., J Clin Exp Dermatol Res 2012, 3:4 l g y C f R o e DOI: 10.4172/2155-9554.1000154 l ISSN: 2155-9554 s a e n a r r u c o h J Dermatology Research Research Article Open Access Chronic Actinic Damage in Pigmented and Depigmented Skin of Hispanic Patients with Vitiligo: Clinical and Histological Differences Maria Teresa Garcia-Romero1*, Ochoa-Sánchez Patricia Esmeralda1, Díaz-Lozano Marisol2, Toussaint-Caire Sonia2 and Lacy-Niebla Rosa Maria1 1Departamento de Dermatología, Hospital General, Dr. Manuel Gea González, México D.F., México 2Sección de Dermatopatología, Hospital General, Dr. Manuel Gea González, México D.F., México Abstract Vitiligo is a common depigmentary disorder, with loss of epidermal Melanocytes as its hallmark. This absence of melanin hypothetically makes skin more susceptible to Chronic Actinic Damage (CAD) and skin cancer development. However, various studies have shown no increased incidence of skin cancer and some point to decreased actinic damage in skin with vitiligo. We studied 14 patients with vitiligo and analyzed clinical and histological markers of chronic actinic damage both in depigmented skin with vitiligo and in normal skin. We found fewer markers of clinical CAD in depigmented skin than in normally pigmented skin. When we analyzed histological, we found that in most patient’s depigmented skin had increased hyperkeratosis, which is a previously reported finding, as well as atrophy, elastosis and telangiectasias. There are various hypotheses to explain these findings.
    [Show full text]
  • Mucocutaneous Manifestations of Neurofibromatosis Type-1: a Clinical Profile of 51 Indian Patients
    Research Mucocutaneous Manifestations of Neurofibromatosis Type-1: A Clinical Profile of 51 Indian Patients Sudip Kumar Ghosh,1* MD, Debabrata Bandyopadhyay,1 MD, Arghyaprasun Ghosh,1 MD, Sharmila Sarkar,2 M.D Address: 1Department of Dermatology, Venereology & Leprosy, RG Kar Medical College, Kolkata, West Bengal, India and 2Department of Psychiatry, Medical College Calcutta, West Bengal, India E-mail: [email protected] * Corresponding author: Dr. Sudip Kumar Ghosh, Vill + P.O.- Rajballavpur (Via-Maslandpur) Dist.-24 Parganas (N) West Bengal, India Published: J Turk Acad Dermatol 2008; 2 (4):jtad82401a This article is available from: http://www.jtad.org/2008/4/jtad82401a.pdf Key Words: neurofibromatosis type-1, mucocutaneous, neurofibroma, café-au-lait macules Abstract Introduction: Neurofibromatosis (NF) is an autosomal dominant neuro-cutaneous disorder. Eight sub- types of the disease have been proposed till date; neurofibromatosis type –1 (NF1) being the com- monest variety. Objective: Objective of our present study had been to review the prevalence and patterns of muco-cutaneous manifestations amongst patients of NF-1, in a population from eastern India. Methods: This was a clinical, observational, cross sectional study. Results: A total of 51 patients were evaluated. The mean age of the patients was 22.6 years with a male-to-female ratio of 0.7. Positive family history in first-degree relatives was found in 18 (35.3%) pa- tients. Forty-nine patients (96.1%) had neurofibromas including 8 (15.7%) patients of plexiform neu- rofibromas. All of our patients had café-au-lait macules (CALM) and freckling was present in 49 (96.1%) patients.
    [Show full text]
  • Clinical Applications of Psoralens, and Related Materials: Vitiligo—What Is
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE Part V provided by Elsevier - Publisher Connector Clinical Applications of Psoralens, and Related Materials VITILIGO—WHAT IS IT?' HERMANN PINKUS, M.D. 'When I first became interested in vitiligo incourse with and without therapy, and reading connection with psoralen therapy, the answer towhatever could be found in the literature, the the question: what is vitiligo? seemed to be verypicture has become more diversified and even simple. Every textbook gives a clear-cut defini-more puzzling. tion. CLINICAL MORPhOLOGy DEFINITION Concerning the clinical picture and course, it To quote Ormsby-Montgomery (1): "Vitiligois certainly true that most lesions show a com- is an acquired cutaneous achromia characterizedplete absence of pigment and a tendency to by variously sized and shaped single or multipleprogress. However, some patients report that patches of milk white color, usually presentingevery summer, on exposure to sunshine, there is hyperpigmented borders and a tendency tosome repigmentation from the borders, and small enlarge peripherally." The authors add to this:pigmented, freckle-like spots may appear in the "Absence of pigment. .. isthe only symptom incenter of white areas, only to disappear again during the winter. The difference is a real one and vitiligo". .. "Theskin. .. presentsno textural changes and is normal in every way except ais not due to enhanced color contrast between sensitiveness to solar irradiation". .. "thecausetanned and vitiliginous skin in the summer. Re- of vitiligo is unknown". .. "thetreatment of thepigmentation of some degree occurs in 50% of disorder is unsatisfactory". patients according to Lerner (2).
    [Show full text]